Teva Pharmaceutical Industries (TEVA) Retained Earnings (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Retained Earnings for 18 consecutive years, with $28.2 billion the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings rose 0.85% year-over-year to $28.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 billion (up 0.85% YoY) and the FY2025 annual result came in at $28.1 billion, up 1.33% from the prior year.
• Retained Earnings steadied at $28.2 billion in Q1 2026 per TEVA's latest filing, from $28.1 billion in the prior quarter.
• Over the last five years, Retained Earnings for TEVA reached as high as $28.2 billion in Q1 2026 and fell as low as -$14.1 billion in Q2 2023.
• A 5-year average of $9.3 billion and a median of -$2.7 billion in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 379.72% — and 2024, when it jumped 1129.44%.
• Year by year, Retained Earnings stood at -$2.8 billion in 2022, then increased by 4.97% to -$2.7 billion in 2023, then soared by 1129.44% to $27.8 billion in 2024, then climbed by 1.33% to $28.1 billion in 2025, then climbed by 0.25% to $28.2 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $28.2 billion, $28.1 billion, and $28.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.